MODEL SPOTLIGHT | Modeling Human Acute Lymphoblastic Leukemia (ALL)

Using the NALM6-Luc-mCh-Puro Model for the Development of CAR T Cell Therapies

Image of ALL cellsAcute lymphoblastic leukemia (ALL) is a cancer of the lymphoid lineage characterized by the development of increased numbers of immature lymphocytes. ALL is a relatively rare cancer; however, it is the most common childhood cancer, which makes it of interest to researchers. Standard therapies for ALL include the use of aggressive or long-term chemotherapy. These treatment regimens result in 90% of children surviving after five years, but this drops to around 40% of adult patients remaining disease free. Due to this relapse rate, other treatment options have been sought.

In recent years, CAR T cells for ALL have been approved for commercial use, however, there is a need for new models that will help in the development of a next generation of therapies. In our model spotlight this month we talk about our in-house establishment of NALM6-Luc-mCh-Puro in NSG mice as a model for ALL and show data on its growth kinetics and survival times. Learn more about this model by reading the full article.

Download the PDF instantly by filling out the form on this page.